Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 809816, 13 pages
http://dx.doi.org/10.1155/2014/809816
Research Article

Lead Screening for CXCR4 of the Human HIV Infection Receptor Inhibited by Traditional Chinese Medicine

1Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan
2School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan
3Department of Neurosurgery, China Medical University Hospital, No. 2, Yude Road, North District, Taichung City 40447, Taiwan
4Department of Anesthesiology, China Medical University Hospital, Taichung 40447, Taiwan
5Research Center for Chinese Medicine & Acupuncture, China Medical University, Taichung 40402, Taiwan

Received 22 February 2014; Revised 5 March 2014; Accepted 5 March 2014; Published 5 June 2014

Academic Editor: Chung Y. Hsu

Copyright © 2014 Tzu-Chieh Hung et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Tan, Y. Zhu, J. Li et al., “Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex,” Science, vol. 341, no. 6152, pp. 1387–1390, 2013. View at Publisher · View at Google Scholar
  2. F. B. Sinoussi, J. C. Chermann, and F. Rey, “Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS),” Science, vol. 220, no. 4599, pp. 868–871, 1983. View at Google Scholar · View at Scopus
  3. M. W. Cloyd, J. J.-Y. Chen, and L. Wang, “How does HIV cause AIDS? The homing theory,” Molecular Medicine Today, vol. 6, no. 3, pp. 108–111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. R. A. Weiss, “How does HIV cause AIDS?” Science, vol. 260, no. 5112, pp. 1273–1279, 1993. View at Google Scholar · View at Scopus
  5. D. C. Douek, M. Roederer, and R. A. Koup, “Emerging concepts in the immunopathogenesis of AIDS,” Annual Review of Medicine, vol. 60, pp. 471–484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Weller and K. Davis, “Condom effectiveness in reducing heterosexual HIV transmission,” The Cochrane Database of Systematic Reviews, no. 1, 2002. View at Google Scholar · View at Scopus
  7. B. Leynaert, A. M. Downs, and I. De Vincenzi, “Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection,” American Journal of Epidemiology, vol. 148, no. 1, pp. 88–96, 1998. View at Google Scholar · View at Scopus
  8. D. M. Bell, “Occupational risk of human immunodeficiency virus infection in healthcare workers: an overview,” The American Journal of Medicine, vol. 102, no. 5 B, pp. 9–15, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. J. L. Cleveland, L. Barker, B. F. Gooch, E. M. Beltrami, and D. Cardo, “Use of HIV postexposure prophylaxis by dental health care personnel: an overview and updated recommendations,” Journal of the American Dental Association, vol. 133, no. 12, pp. 1619–1626, 2002. View at Google Scholar · View at Scopus
  10. J. C. Forbes, A. M. Alimenti, J. Singer et al., “A national review of vertical HIV transmission,” AIDS, vol. 26, no. 6, pp. 757–763, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. K. M. Little, P. H. Kilmarx, A. W. Taylor, C. E. Rose, E. D. Rivadeneira, and S. R. Nesheim, “A review of evidence for transmission of HIV from children to breastfeeding women and implications for prevention,” Pediatric Infectious Disease Journal, vol. 31, no. 9, pp. 938–942, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Finzi, M. Hermankova, T. Pierson et al., “Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy,” Science, vol. 278, no. 5341, pp. 1295–1300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Wu, E. Y. T. Chien, C. D. Mol et al., “Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists,” Science, vol. 330, no. 6007, pp. 1066–1071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. E. A. Berger, P. M. Murphy, and J. M. Farber, “Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease,” Annual Review of Immunology, vol. 17, pp. 657–700, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Coakley, C. J. Petropoulos, and J. M. Whitcomb, “Assessing chemokine co-receptor usage in HIV,” Current Opinion in Infectious Diseases, vol. 18, no. 1, pp. 9–15, 2005. View at Google Scholar · View at Scopus
  16. V. M. Muniz-Medina, S. Jones, J. M. Maglich et al., “The relative activity of “function sparing” HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?” Molecular Pharmacology, vol. 75, no. 3, pp. 490–501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. W.-T. Choi, R. Nedellec, M. Coetzer et al., “CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity,” Journal of Virology, vol. 86, no. 18, pp. 10218–10220, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. H.-J. Huang, H. W. Yu, C.-Y. Chen et al., “Current developments of computer-aided drug design,” Journal of the Taiwan Institute of Chemical Engineers, vol. 41, no. 6, pp. 623–635, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. W. I. Tou, S.-S. Chang, C.-C. Lee, and C. Y.-C. Chen, “Drug design for neuropathic pain regulation from traditional Chinese medicine,” Scientific Reports, vol. 3, p. 844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Y.-C. Chen, “A novel integrated framework and improved methodology of computer-aided drug design,” Current Topics in Medicinal Chemistry, vol. 13, no. 9, pp. 965–988, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Y.-C. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. W.-L. Liao and F.-J. Tsai, “Personalized medicine: a paradigm shift in healthcare,” BioMedicine, vol. 3, no. 2, pp. 66–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. F.-J. Tsai, “Biomedicine brings the future nearer,” BioMedicine, vol. 1, no. 1, p. 1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. C.-C. Lee, C.-H. Tsai, L. Wan et al., “Increased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central Taiwan,” BioMedicine, vol. 3, no. 2, pp. 92–94, 2013. View at Publisher · View at Google Scholar
  25. W.-Y. Lin, H.-P. Liu, J.-S. Chang et al., “Genetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formation,” BioMedicine, vol. 3, no. 2, pp. 73–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. C.-H. Wang, W.-D. Lin, D.-T. Bau, I.-C. Chou, C.-H. Tsai, and F.-J. Tsai, “Appearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathway,” BioMedicine, vol. 3, no. 2, pp. 82–81, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. Y.-M. Chang, B. K. Velmurugan, W.-W. Kuo et al., “Inhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cells,” BioMedicine, vol. 3, no. 4, pp. 148–152, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. F.-J. Tsai, “Rare diseases: a mysterious puzzle,” BioMedicine, vol. 3, no. 2, p. 65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. I. C. Chou, W.-D. Lin, C.-H. Wang et al., “Möbius syndrome in a male with XX/XY mosaicism,” BioMedicine, vol. 3, no. 2, pp. 102–104, 2013. View at Google Scholar
  30. Y.-T. Chang, W.-D. Lin, Z.-N. Chin et al., “Nonketotic hyperglycinemia: a case report and brief review,” BioMedicine, vol. 2, no. 2, pp. 80–82, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. C.-H. Wang, W.-D. Lin, and F.-J. Tsai, “Craniofacial dysmorphism, what is your diagnosis?” BioMedicine, vol. 2, no. 2, pp. 49–50, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Y.-C. Chen, “TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening In Silico,” PLoS ONE, vol. 6, no. 1, Article ID e15939, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. H.-J. Huang, K.-J. Lee, H. W. Yu et al., “Structure-based and ligand-based drug design for HER 2 receptor,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 1, pp. 23–37, 2010. View at Google Scholar · View at Scopus
  34. W. I. Tou and C. Y.-C. Chen, “Traditional Chinese medicine as dual guardians against hypertension and cancer?” Journal of Biomolecular Structure and Dynamics, vol. 30, no. 3, pp. 299–317, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. S.-C. Yang, S.-S. Chang, and C. Y.-C. Chen, “Identifying HER2 inhibitors from natural products database,” PLoS ONE, vol. 6, no. 12, Article ID e28793, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C.-Y. Chen and C. Y.-C. Chen, “Insights into designing the dual-targeted HER2/HSP90 inhibitors,” Journal of Molecular Graphics and Modelling, vol. 29, no. 1, pp. 21–31, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. K.-C. Chen and C. Y.-C. Chen, “Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach,” Soft Matter, vol. 7, no. 8, pp. 4001–4008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. S.-C. Yang, S.-S. Chang, H.-Y. Chen, and C. Y.-C. Chen, “Identification of potent EGFR inhibitors from TCM Database@Taiwan,” PLoS Computational Biology, vol. 7, no. 10, Article ID e1002189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. K.-C. Chen, M.-F. Sun, S.-C. Yang et al., “Investigation into potent inflammation inhibitors from traditional Chinese medicine,” Chemical Biology and Drug Design, vol. 78, no. 4, pp. 679–688, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@Taiwan,” Molecular BioSystems, vol. 7, no. 12, pp. 3366–3374, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. C.-H. Lin, T.-T. Chang, M.-F. Sun et al., “Potent inhibitor design against H1N1 swine influenza: structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database,” Journal of Biomolecular Structure and Dynamics, vol. 28, no. 4, pp. 471–482, 2011. View at Google Scholar · View at Scopus
  42. S.-S. Chang, H.-J. Huang, and C. Y.-C. Chen, “Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine,” PLoS Computational Biology, vol. 7, no. 12, Article ID e1002315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. C.-Y. Chen, Y.-H. Chang, D.-T. Bau et al., “Ligand-based dual target drug design for H1N1: swine flu—a preliminary first study,” Journal of Biomolecular Structure and Dynamics, vol. 27, no. 2, pp. 171–178, 2009. View at Google Scholar · View at Scopus
  44. T.-Y. Tsai, K.-W. Chang, and C. Y.-C. Chen, “IScreen: world's first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan,” Journal of Computer-Aided Molecular Design, vol. 25, no. 6, pp. 525–531, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. K.-W. Chang, T.-Y. Tsai, K.-C. Chen et al., “iSMART: an integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug design,” Journal of Biomolecular Structure and Dynamics, vol. 29, no. 1, pp. 243–250, 2011. View at Google Scholar · View at Scopus
  46. W. I. Tou and C. Y. Chen, “May disordered protein cause serious drug side effect?” Drug Discovery Today, vol. 19, no. 4, pp. 367–372, 2013. View at Publisher · View at Google Scholar
  47. C. Y.-C. Chen and W. I. Tou, “How to design a drug for the disordered proteins?” Drug Discovery Today, vol. 18, no. 19-20, pp. 910–915, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. B. R. Brooks, C. L. Brooks III, A. D. Mackerell Jr. et al., “CHARMM: the biomolecular simulation program,” Journal of Computational Chemistry, vol. 30, no. 10, pp. 1545–1614, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. C. M. Venkatachalam, X. Jiang, T. Oldfield, and M. Waldman, “LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites,” Journal of Molecular Graphics and Modelling, vol. 21, no. 4, pp. 289–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. R. A. Laskowski and M. B. Swindells, “LigPlot+: multiple ligand-protein interaction diagrams for drug discovery,” Journal of Chemical Information and Modeling, vol. 51, no. 10, pp. 2778–2786, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. A. C. Wallace, R. A. Laskowski, and J. M. Thornton, “LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions,” Protein Engineering, vol. 8, no. 2, pp. 127–134, 1995. View at Google Scholar · View at Scopus
  52. V. Zoete, M. A. Cuendet, A. Grosdidier, and O. Michielin, “SwissParam: a fast force field generation tool for small organic molecules,” Journal of Computational Chemistry, vol. 32, no. 11, pp. 2359–2368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. U. D. Priyakumar and A. D. MacKerell, “Comparison of the CHARMM27, AMBER4. 1 and BMS nucleic acid force fields via free energy calculations of base flipping,” Abstracts of Papers of the American Chemical Society, vol. 230, pp. U1391–U1392, 2005. View at Google Scholar
  54. B. Hess, C. Kutzner, D. Van Der Spoel, and E. Lindahl, “GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation,” Journal of Chemical Theory and Computation, vol. 4, no. 3, pp. 435–447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. T. A. Darden and L. G. Pedersen, “Molecular modeling: an experimental tool,” Environmental Health Perspectives, vol. 101, no. 5, pp. 410–412, 1993. View at Google Scholar · View at Scopus
  56. M. Yoshikawa, S. Hatakeyama, Y. Inoue, and J. Yamahara, “Saussureamines A, B, C, D, and E, new anti-ulcer principles from Chinese Saussureae radix,” Chemical and Pharmaceutical Bulletin, vol. 41, no. 1, pp. 214–216, 1993. View at Google Scholar · View at Scopus
  57. Y. K. Choi, S.-G. Cho, and S.-M. Woo, “Saussurea lappa clarke-Derived costunolide prevents TNF alpha induced breast cancer cell migration and invasion by inhibiting NF-κB activity,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 936257, 10 pages, 2013. View at Publisher · View at Google Scholar
  58. O. P. Upadhyay, J. K. Ojha, H. S. Bajpai, and A. K. Hathwal, “Study of kustha (saussurea lappa, clarke) in ischaemic heart disease,” Ancient Science of Life, vol. 13, no. 1-2, pp. 11–18, 1993. View at Google Scholar
  59. T. S. M. Saleem, N. Lokanath, A. Prasanthi, M. Madhavi, G. Mallika, and M. N. Vishnu, “Aqueous extract of Saussurea lappa root ameliorate oxidative myocardial injury induced by isoproterenol in rats,” Journal of Advanced Pharmaceutical Technology and Research, vol. 4, no. 2, pp. 94–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Yaeesh, Q. Jamal, A. J. Shah, and A. H. Gilani, “Antihepatotoxic activity of Saussurea lappa extract on D-galactosamine and lipopolysaccharide-induced hepatitis in mice,” Phytotherapy Research, vol. 24, no. 2, pp. S229–S232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Taniguchi, T. Kattaoka, H. Suzuki et al., “Costunolide and dehydrocostus lactone as inhibitors of killing function of cytotoxic T lymphocytes,” Bioscience, Biotechnology and Biochemistry, vol. 59, no. 11, pp. 2064–2067, 1995. View at Google Scholar · View at Scopus
  62. S. K. Yadav, J. Prakash, S. Chouhan, and S. P. Singh, “Mucuna pruriens seed extract reduces oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in paraquat-induced Parkinsonian mouse model,” Neurochemistry International, vol. 62, no. 8, pp. 1039–1047, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Ovallath and P. Deepa, “The history of parkinsonism: descriptions in ancient Indian medical literature,” Movement Disorders, vol. 28, no. 5, pp. 566–568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Phatarphekar, J. M. Buss, and S. E. Rokita, “Iodotyrosine deiodinase: a unique flavoprotein present in organisms of diverse phyla,” Molecular BioSystems, vol. 10, no. 1, pp. 86–92, 2014. View at Publisher · View at Google Scholar
  65. K. B. Paul, J. M. Hedge, C. Macherla et al., “Cross-species analysis of thyroperoxidase inhibition by xenobiotics demonstrates conservation of response between pig and rat,” Toxicology, vol. 312, no. 1, pp. 97–107, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Toth and B. Noszal, “Thyroid hormones and their precursors I. Biochemical properties,” Acta Pharmaceutica Hungarica, vol. 83, no. 2, pp. 35–45, 2013. View at Google Scholar
  67. D. H. Haas and R. M. Murphy, “Design of a pH-sensitive pore-forming peptide with improved performance,” Journal of Peptide Research, vol. 63, no. 1, pp. 9–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Chovancova, A. Pavelka, P. Benes et al., “CAVER 3.0: a tool for the analysis of transport pathways in dynamic protein structures,” PLoS Computational Biology, vol. 8, no. 10, Article ID e1002708, 2012. View at Publisher · View at Google Scholar · View at Scopus